George S. Laszlo

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington et al. · Blood · 2013 · 173 citations · Full text

Life Sciences, Immunology, Oncology +14

Increased Basal cAMP-dependent Protein Kinase Activity Inhibits the Formation of Mesoderm-derived Structures in the Developing Mouse Embryo

Paul S. Amieux, Douglas G. Howe, Heidi Knickerbocker et al. · Journal of Biological Chemistry · 2002 · 108 citations · Full text

Life Sciences, Developmental Biology, Genetics +17

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Olivier Humbert, George S. Laszlo, Sophie R Sichel et al. · Leukemia · 2018 · 78 citations

Life Sciences, Hematology, Molecular Genetics +14

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon et al. · Journal of Hematology & Oncology · 2015 · 61 citations · Full text

Medicine, Hematology, Oncology +14

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

Kimberly H. Harrington, Chelsea J. Gudgeon, George S. Laszlo et al. · PLoS ONE · 2015 · 61 citations · Full text

Life Sciences, Hematology, Immunology +16